Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Factors Influencing Drug Absorption: Presystemic Elimination01:24

Factors Influencing Drug Absorption: Presystemic Elimination

834
The pharmacokinetic journey of oral drugs begins with a crucial first pass through the hepatic portal system, called the first-pass effect. This first pass significantly impacts bioavailability — the proportion of a drug that enters systemic circulation and is available for therapeutic action. The primary route sees the drug absorbed by intestinal membranes and then shunted to the liver via the hepatic portal vein. Here, pre-systemic elimination occurs as drugs face metabolism or biliary...
834
Non-Oral Extravascular Drug Absorption Routes01:15

Non-Oral Extravascular Drug Absorption Routes

490
Non-oral extravascular routes, which encompass sublingual, buccal, topical, intramuscular, and inhalation methods, primarily utilize passive diffusion to transport drugs into the systemic circulation. The absorption rates and effectiveness of these routes depend on the drug's physicochemical properties, as well as the patient's anatomical and pathophysiological state.
Lipophilic drugs that are stable at salivary pH (6) and exhibit minimal binding to the oral mucosa are absorbed more...
490
Bioavailability: Overview01:17

Bioavailability: Overview

377
Bioavailability refers to the proportion of an administered drug that reaches the systemic circulation in its active, unaltered form. It is a crucial pharmacokinetic parameter that determines the effectiveness of a drug in achieving its intended therapeutic outcomes. The route of administration significantly influences bioavailability, with intravenous administration achieving 100% bioavailability as the drug directly enters the bloodstream. In contrast, oral administration often results in...
377
Bioavailability: Overview01:13

Bioavailability: Overview

4.2K
Bioavailability refers to the proportion of an unaltered drug that, after administration, enters the systemic circulation and can be distributed to the desired action site. Factors such as gastrointestinal (GI) absorption and liver biotransformation influence the bioavailability of a drug when it is administered orally. When a drug is administered intravenously, it enters the systemic circulation directly; by definition, its bioavailability is assumed to be 100%. The bioavailability of an...
4.2K
Bioavailability Study Design: Single Versus Multiple Dose Studies01:11

Bioavailability Study Design: Single Versus Multiple Dose Studies

217
Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...
217
Bioavailability Study Design: Healthy Subjects Versus Patients01:15

Bioavailability Study Design: Healthy Subjects Versus Patients

144
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
144

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A pilot randomized feasibility clinical trial of intranasal vs. intravenous naloxone in pediatric opioid poisoning.

Drug and alcohol dependence·2026
Same author

Impact of the FTO rs9939609 risk allele on subcutaneous adipose tissue fatty acid composition in adults with obesity class 2 and 3.

PloS one·2026
Same author

Ethanol pharmacokinetics before and after sleeve gastrectomy and Roux-en-Y gastric bypass: a 3 year prospective study (the BAR-TRIAL).

International journal of obesity (2005)·2026
Same author

Spotting opioid arrest when no one sees it.

Resuscitation·2025
Same author

From fairytale to clinical practice: A response to commentaries.

Addiction (Abingdon, England)·2025
Same author

Pharmacokinetics of subcutaneous and intravenous bolus doses of morphine in palliative care cancer patients receiving infusion of morphine: A pharmacokinetic substudy of a randomized controlled trial.

British journal of clinical pharmacology·2025

Related Experiment Video

Updated: Jan 19, 2026

Novel Methods for Intranasal Administration Under Inhalation Anesthesia to Evaluate Nose-to-Brain Drug Delivery
05:44

Novel Methods for Intranasal Administration Under Inhalation Anesthesia to Evaluate Nose-to-Brain Drug Delivery

Published on: November 14, 2018

21.1K

Naloxone nasal spray - bioavailability and absorption pattern in a phase 1 study.

Ida Tylleskar, Arne Kristian Skulberg, Turid Nilsen

    Tidsskrift for Den Norske Laegeforening : Tidsskrift for Praktisk Medicin, Ny Raekke
    |September 27, 2019
    PubMed
    Summary

    This study shows that a new, highly concentrated naloxone nasal spray provides rapid and effective systemic absorption of naloxone, potentially offering a life-saving intervention for opioid overdose.

    More Related Videos

    Modeling and Simulations of Olfactory Drug Delivery with Passive and Active Controls of Nasally Inhaled Pharmaceutical Aerosols
    15:04

    Modeling and Simulations of Olfactory Drug Delivery with Passive and Active Controls of Nasally Inhaled Pharmaceutical Aerosols

    Published on: May 20, 2016

    11.4K
    Technical Aspect of the Automated Synthesis and Real-Time Kinetic Evaluation of [11C]SNAP-7941
    09:50

    Technical Aspect of the Automated Synthesis and Real-Time Kinetic Evaluation of [11C]SNAP-7941

    Published on: April 28, 2019

    8.0K

    Related Experiment Videos

    Last Updated: Jan 19, 2026

    Novel Methods for Intranasal Administration Under Inhalation Anesthesia to Evaluate Nose-to-Brain Drug Delivery
    05:44

    Novel Methods for Intranasal Administration Under Inhalation Anesthesia to Evaluate Nose-to-Brain Drug Delivery

    Published on: November 14, 2018

    21.1K
    Modeling and Simulations of Olfactory Drug Delivery with Passive and Active Controls of Nasally Inhaled Pharmaceutical Aerosols
    15:04

    Modeling and Simulations of Olfactory Drug Delivery with Passive and Active Controls of Nasally Inhaled Pharmaceutical Aerosols

    Published on: May 20, 2016

    11.4K
    Technical Aspect of the Automated Synthesis and Real-Time Kinetic Evaluation of [11C]SNAP-7941
    09:50

    Technical Aspect of the Automated Synthesis and Real-Time Kinetic Evaluation of [11C]SNAP-7941

    Published on: April 28, 2019

    8.0K

    Area of Science:

    • Pharmacology
    • Drug Delivery Systems

    Background:

    • Naloxone nasal spray is crucial for preventing opioid overdose deaths.
    • Optimal nasal absorption requires low-volume, high-concentration naloxone formulations.
    • A new naloxone nasal spray formulation was developed to improve bioavailability.

    Purpose of the Study:

    • To evaluate the bioavailability and absorption characteristics of a novel naloxone nasal spray.
    • To compare the pharmacokinetic profile of the intranasal naloxone spray with intravenous administration.

    Main Methods:

    • A randomized, two-way crossover study in five healthy males.
    • Comparison of intranasal naloxone (2 mg) with intravenous naloxone (1 mg).
    • Blood samples collected over six hours; drug concentration analyzed via LC-MS/MS; pharmacokinetic variables calculated using non-compartmental analysis.

    Main Results:

    • Intranasal naloxone bioavailability was 47% (range 24-66%).
    • Maximum serum concentration (Cmax) of 4.2 ng/ml was reached at Tmax of 16 minutes.
    • Rapid systemic absorption observed, with higher serum concentrations than IV naloxone from 10-240 minutes post-administration.

    Conclusions:

    • The highly concentrated naloxone nasal spray demonstrated rapid systemic absorption.
    • A single actuation may deliver a therapeutic dose, suggesting potential for commercial development.
    • This formulation shows promise as an effective intervention for opioid overdose.